Justin Kim analyst OPPENHEIMER

Currently out of the existing stock ratings of Justin Kim, 81 are a BUY (92.05%), 7 are a HOLD (7.95%).

Justin Kim

Work Performance Price Targets & Ratings Chart

Analyst Justin Kim, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 60.52% that have a potential upside of 63.38% achieved within 303 days.

Justin Kim’s has documented 167 price targets and ratings displayed on 15 stocks. The coverage is on Healthcare, Consumer Cyclical sectors.

Most recent stock forecast was given on PHVS, Pharvaris BV at 04-Dec-2025.

Wall Street Analyst Justin Kim

Analyst best performing recommendations are on VERA (VERA THERAPEUTICS).
The best stock recommendation documented was for VERA (VERA THERAPEUTICS) at 1/24/2024. The price target of $26 was fulfilled within 2 days with a profit of $8.98 (52.76%) receiving and performance score of 263.81.

Average potential price target upside

ANGN Angion Biomedica Corp APLS Apellis Pharmaceuticals AUPH Aurinia Pharmaceuticals BCRX BioCryst Pharmaceuticals CYTK Cytokinetics PRVB Provention Bio PHVS Pharvaris BV ALDX Aldeyra The IMCR Immunocore Holdings Ltd KDNY Chinook Therapeutics IONS Ionis Pharmaceuticals ALPN Alpine Immune Sciences AN AutoNation KD Kyndryl Holdings VERA Vera Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 18-Jul-2022

$280

3 years 8 months 12 days ago
(18-Jul-2022)

0/4 (0%)

$267.6 (2158.06%)

Hold Since 30-Jun-2022

$50

$40 (400.00%)

$150

3 years 9 months ago
(30-Jun-2022)

0/4 (0%)

$38.6 (338.60%)

Hold Since 30-Jun-2022

3 years 9 months ago
(30-Jun-2022)

0/2 (0%)

$53.9 (206.51%)

Show more analysts

Please expand the browser size to see the chart

Which stock is Justin Kim is most bullish on?

Potential upside of $22.65 has been obtained for PHVS (PHARVARIS BV)

What Year was the first public recommendation made by Justin Kim?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?